The Computerized Multiphasic Interactive
Neurocognitive DualDisplayTM System
(CMINDS®) is a next-generation neurocognitive and behavioral
assessment system that is uniquely defined by a DualDisplayTM
architecture that integrates rather than replaces an Examiner in the
process of evaluation. This architecture affords advanced capabilities
especially relevant for assessment of people who require ongoing assistance to
understand and complete testing.
CMINDS® hosts over 30
fully computerized neurocognitive tests, the widest range available. Accordingly, CMINDS® is
applicable across a wide spectrum of central nervous system disorders,
including:
- Alzheimer's Disease,
-
Schizophrenia,
- Traumatic Brain Injury (TBI),
-
Neurotoxicological insult,
- Stroke,
-
HIV encephalopathy and
- other acquired brain
disorders.
CMINDS® provides a multimedia-capable platform that
features digitally recorded human-voice instructions, detailed report
generation, integrated data management utilities and integrated examiner
training modules for certification-contingent access control.
CMINDS® is
fully compatible with and shares a common database with
ClintabTM, a mobile, tablet PC-based, data capture system which hosts key behavioral and psychiatric measures for clinical trials. This allows all assessment data
collected for clinical trials to be integrated immediately.
CMINDS® has
been utilized in Phase I, II & III clinical trails, as well as
investigator-initiated studies, at over 100 leading institutions throughout the
U.S., Canada and South America over the past 8 years.
The development of CMINDS® was funded by the National
Institute of Mental Health (NIMH)* and the National Institute on Aging (NIA)**
to provide efficient computerized versions of commonly applied, established
tests, as opposed to unique or proprietary designs.